Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961350 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
A Phase 3 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT00961350 is a Phase 3 study that has completed, run by POZEN. The registered enrollment target is 530 participants.
The verdict
NCT00961350, a Phase 3 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
Primary: To demonstrate that PA32540 causes fewer gastric ulcers in subjects at risk for developing aspirin-associated gastric ulcers compared to enteric coated (EC) aspirin 325 mg.
Interventions
- DRUG PA32540
- DRUG EC Aspirin 325
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00961350
The ClinicalTrials.gov registry entry for NCT00961350 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PA32540 is the first listed.
NCT00961350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00961350 about?
NCT00961350 is a clinical study titled "A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers". Primary: To demonstrate that PA32540 causes fewer gastric ulcers in subjects at risk for developing aspirin-associated gastric ulcers compared to enteric coated (EC) aspirin 325 mg.
What is the current status of trial NCT00961350?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2009-10. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00961350?
The interventions under investigation include: PA32540 (DRUG), EC Aspirin 325 (DRUG).
Who is sponsoring clinical trial NCT00961350?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.